Last reviewed · How we verify

Comparator: placebo metformin — Competitive Intelligence Brief

Comparator: placebo metformin (Comparator: placebo metformin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: placebo metformin (Comparator: placebo metformin) — Merck Sharp & Dohme LLC. Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Comparator: placebo metformin TARGET Comparator: placebo metformin Merck Sharp & Dohme LLC phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin+ gliclazide metformin+ gliclazide GlaxoSmithKline marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
Liraglutide + metformin Liraglutide + metformin University Medical Centre Ljubljana marketed GLP-1 receptor agonist + biguanide combination GLP-1 receptor; metformin targets mitochondrial glycerophosphate dehydrogenase
Mandated back ground therapy Mandated back ground therapy Sanofi marketed biguanide
Pioglitazone vs Metformin Pioglitazone vs Metformin Post Graduate Institute of Medical Education and Research, Chandigarh marketed Antidiabetic agents (thiazolidinedione vs. biguanide) Pioglitazone: PPAR-γ; Metformin: AMPK
Pioglitazone and Metformin Pioglitazone and Metformin Takeda marketed Thiazolidinedione + Biguanide combination PPAR-γ (pioglitazone); Complex I of mitochondrial respiratory chain (metformin)
"Metformin" and "Mitiglinide" "Metformin" and "Mitiglinide" Third Affiliated Hospital of Third Military Medical University marketed Antidiabetic combination (biguanide + meglitinide) Metformin: AMP-activated protein kinase (AMPK); Mitiglinide: ATP-sensitive potassium channel (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: placebo metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-placebo-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: